CervoMed Inc.

Item 7.01. Regulation FD Disclosure. On October 12, 2026, CervoMed Inc. (the “Company”) issued a press release announcing initial data from the first 12 weeks of the Company’s Phase 2a clinical trial in nonfluent variant primary progressive aphasia (“nfvPPA”), which were presented in a late-breaking oral presentation at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia, Pennsylvania. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in or incorporated by reference into this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events. The information set forth in the first paragraph of, and in the first, second, and fourth paragraphs under the heading, “Initial Biomarker Data from the Phase 2a Study in nfvPPA” in, the Company’s press release issued on October 12, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.